Detail info about the product:
Packing: bottle 500 mg
The activity of TIENAM against an unusually broad spectrum of pathogens makes it particularly useful in the treatment of polymicrobic and mixed aerobic/anaerobic infections, as well as initial therapy prior to the identification of the causative organisms. TIENAM is indicated for the treatment of the following infections due to susceptible organisms:
Lower respiratory tract infections
Genitourinary tract infections
Bone and joint infections
Skin and soft tissue infections
Not indicated for therapy with the intramuscular formulation.
TIENAM is indicated for the treatment of mixed infections caused by susceptible strains of aerobic and anaerobic bacteria. The majority of these mixed infections are associated with contamination by fecal flora or flora originating from the vagina, skin and mouth. In these mixed infections, Bacteroides fragilis is the most commonly encountered anaerobic pathogen and is usually resistant to aminoglycosides, cephalosporins and penicillins. However, Bacteroides fragilis is usually susceptible to TIENAM.
TIENAM is not indicated for the treatment of meningitis.
DOSAGE AND ADMINISTRATION
TIENAM is available in two different formulations, one for intravenous infusion only and one for intramuscular injection only. THE INTRAMUSCULAR FORMULATION MUST NOT BE USED INTRAVENOUSLY.
Dosage and administration recommendations for the INTRAVENOUS INFUSION are presented first.
The dosage recommendations for TIENAM represent the quantity of imipenem to be administered. An equivalent amount of cilastatin is also present.
The total daily dosage and route of administration of TIENAM should be based on the type or severity of infection and given in equally divided doses based on consideration of degree of susceptibility of the pathogen(s), renal function and body weight.
Doses cited in Table 1 are based on a patient with normal renal function (creatinine clearance of > 70 mL/min/1.73 m2) and a body weight of ³ 70 kg. A reduction in dose must be made for a patient with a creatinine clearance £ 70 mL/min/1.73 m2 (see Table 2) and/or a body weight < 70 kg. The reduction for body weight is especially important for patients with much lower body weights and/or moderate/severe renal insufficiency.
Most infections respond to a daily dose of 1-2 g administered in 3-4 divided doses . For the treatment of moderate infection, a 1 g b.i.d. dosage regimen may also be used. In infections due to less susceptible organisms, the daily dosage of TIENAM I.V. may be increased to a maximum of 4 g/day or 50 mg/kg/day, whichever is lower.
Each dose of £ 500 mg of TIENAM I.V. should be given by intravenous infusion over 20 to 30 minutes. Each dose > 500 mg should be infused over 40 to 60 minutes. In patients who develop nausea during the infusion, the rate of infusion may be slowed.
Hypersensitivity to any component of this product.
Due to the use of lidocaine HCl as a diluent, TIENAM I.M. is contraindicated in patients with a known hypersensitivity to local anesthetics of the amide type and in patients with severe shock or heart block. (Refer to the circular for lidocaine HCl).